Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response
Association of HMGB1 and HMGB2 genetic polymorphisms with lung cancer chemotherapy response
复制标题
HMGB1 和 HMGB2 基因多态性与肺癌化疗反应的关联。
DOI：
10.1111/1440-1681.12232
复制
发表时间：
2014-06-01
影响因子：
2.9
通讯作者：
Liu, Zhao-Qian
中科院分区：
文献类型：
--
作者：
Wang, Ying;Li, Xiang-Ping;Liu, Zhao-Qian
本研究旨在探讨中国肺癌患者高迁移率族蛋白1和高迁移率族蛋白2(HMGB1和HMGB2)基因多态性与铂类药物化疗疗效的关系。总共有338名中国肺癌患者(154名应答者和184名无应答者)参加了这项研究。所有患者都接受了至少两个周期的一线铂类化疗。检测了HMGB1的3个标记单核苷酸多态(SNPs)和HMGB2的2个标记SNPs。我们发现HMGB1的rs1412125和rs2249825在隐性模型和基因模型中都与铂类药物的化疗反应显著相关。此外，rs1412125在加性、隐性和基因分型模型中与55岁年龄组患者的铂类药物化疗反应显著相关。未检测到其他SNPs与铂类药物化疗反应之间的显著关联。在中国肺癌患者中，HMGB1单核苷酸多态(rs1412125和rs2249825)与铂类药物化疗反应相关。综上所述，HMGB1单核苷酸多态性可作为预测铂类化疗疗效的潜在生物标志物。
The aim of the present study was to investigate the association of genetic polymorphisms in high mobility group box 1 and 2 (HMGB1 and HMGB2, respectively) with platinum-based chemotherapy responses in Chinese lung cancer patients. In total, 338 Chinese lung cancer patients (154 responders and 184 non-responders) were recruited to the study. All patients received at least two cycles of first-line platinum-based chemotherapy. Three tagging single nucleotide polymorphisms (SNPs) of HMGB1 and two tagging SNPs of HMGB2 were detected in patients. We found that rs1412125 and rs2249825 of HMGB1 were significantly associated with the platinum-based chemotherapy response in both recessive and genotypic models. In addition, rs1412125 showed significant association with platinum-based chemotherapy response for the subgroup of patients aged >55years in additive, recessive and genotypic models. No significant associations were detected between other SNPs and the platinum-based chemotherapy response. The HMGB1 SNPs (rs1412125 and rs2249825) were associated with platinum-based chemotherapy responses in Chinese lung cancer patients. In conclusion, HMGB1 SNPs may serve as potential biomarkers for predicting the efficacy of platinum-based chemotherapy.